👏👏👏👏👏 Now that's an action worth taking. In a world teetering at the brink of iatrogenocidal totalitarianism, changing the patent legalities does indeed hit the PharmaCartel where it hurts. Will that be enough to stop the rest of the panoptican prison, no, but it will certainly put a dent in the profit margins, devalue the stocks, and may ultimately remove a large portion of government and private organisations golden mRNA cash cows.🤞🤞😉
As I have previously indicated, patents should only be granted at end of Phase II clinical studies, when the molecule or bio molecule is known and explicitly characterised, and should be applicable only to to those substances thus characterised. This has two benefits, firstly, for the science, as it stops ridiculous spoilage patent coverage by the originator for closely related analogues. Secondly, for the originator, the resulting longer exclusivity post approval helps recoup the development costs and still provide a healthy return on investment. As for mRNA based therapies, they are not a universal panacea. Anyone in a government or regulatory body who thinks they are needs to be replaced with someone scientifically literate. These matters are not for dilettantes or the uninformed but nevertheless opinionated to be regulating.
👏👏👏👏👏 Now that's an action worth taking. In a world teetering at the brink of iatrogenocidal totalitarianism, changing the patent legalities does indeed hit the PharmaCartel where it hurts. Will that be enough to stop the rest of the panoptican prison, no, but it will certainly put a dent in the profit margins, devalue the stocks, and may ultimately remove a large portion of government and private organisations golden mRNA cash cows.🤞🤞😉
#chinkinthearmour #addanothernail #onestep #wearemany #wearememory #wewillnotforgive #mistakeswereNOTmade #getlocalised
Now that's what I call a comment worth paying attention to, BarefootHealer! Thanks so much for your continued insightful comments :O)
2017! You were way ahead of the game.
In fact, I started in 2010 JAS, just before Wiley published my 1st book: https://www.wiley.com/en-gb/Supply+Chain+Management+in+the+Drug+Industry%3A+Delivering+Patient+Value+for+Pharmaceuticals+and+Biologics-p-9780470555170 - from then on, I was known Inside Pharma as a modernizer, presenting at pharmaceutical conferences in UK/EU/US. Thety humoured me, of course, but continued chasing patents and exercising power marketing tactics - now the chickens are coming home to roost!
As I have previously indicated, patents should only be granted at end of Phase II clinical studies, when the molecule or bio molecule is known and explicitly characterised, and should be applicable only to to those substances thus characterised. This has two benefits, firstly, for the science, as it stops ridiculous spoilage patent coverage by the originator for closely related analogues. Secondly, for the originator, the resulting longer exclusivity post approval helps recoup the development costs and still provide a healthy return on investment. As for mRNA based therapies, they are not a universal panacea. Anyone in a government or regulatory body who thinks they are needs to be replaced with someone scientifically literate. These matters are not for dilettantes or the uninformed but nevertheless opinionated to be regulating.